The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine …
CM Wheeler, SK Kjaer, K Sigurdsson… - The Journal of …, 2009 - academic.oup.com
Background We evaluated the impact of a quadrivalent human papillomavirus (HPV)
vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35 …
vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35 …
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial
M Safaeian, C Porras, Y Pan, A Kreimer… - Cancer Prevention …, 2013 - AACR
Abstract The Costa Rica HPV16/18 Vaccine Trial (CVT) showed that four-year vaccine
efficacy against 12-month HPV16/18 persistent infection was similarly high among women …
efficacy against 12-month HPV16/18 persistent infection was similarly high among women …
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial
A Hildesheim, R Herrero, S Wacholder, AC Rodriguez… - Jama, 2007 - jamanetwork.com
ContextViruslike particle human papillomavirus (HPV) vaccines were designed to prevent
HPV infection and development of cervical precancers and cancer. Women with oncogenic …
HPV infection and development of cervical precancers and cancer. Women with oncogenic …
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
EA Joura, SK Kjaer, CM Wheeler, K Sigurdsson… - Vaccine, 2008 - Elsevier
The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be
mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV …
mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV …
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
CD Harro, YYS Pang, RBS Roden… - Journal of the …, 2001 - academic.oup.com
Background: Studies in animal models have shown that systemic immunization with a
papillomavirus virus-like particle (VLP) vaccine composed of L1, a major structural viral …
papillomavirus virus-like particle (VLP) vaccine composed of L1, a major structural viral …
[HTML][HTML] From the monovalent to the nine-valent HPV vaccine
S Pils, EA Joura - Clinical Microbiology and Infection, 2015 - Elsevier
An investigational monovalent human papillomavirus (HPV) 16 virus-like particle vaccine
has been shown to prevent persistent infection and cervical disease related to HPV 16 and …
has been shown to prevent persistent infection and cervical disease related to HPV 16 and …
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV …
SE Olsson, SK Kjaer, K Sigurdsson, OE Iversen… - Human …, 2009 - Taylor & Francis
Objective In the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL®/SILGARD®)
clinical program, 73% of women aged 16-26 were naïve to all vaccine HPV types. In these …
clinical program, 73% of women aged 16-26 were naïve to all vaccine HPV types. In these …
[HTML][HTML] Clinical trials of human papillomavirus vaccines and beyond
M Lehtinen, J Dillner - Nature reviews Clinical oncology, 2013 - nature.com
Human papillomavirus (HPV) is the most common sexually transmitted infectious agent; its
14 oncogenic types are causally associated with 5–10% of all cancers. The major structural …
14 oncogenic types are causally associated with 5–10% of all cancers. The major structural …
A review of clinical trials of human papillomavirus prophylactic vaccines
JT Schiller, X Castellsagué, SM Garland - Vaccine, 2012 - Elsevier
End of study analyses of the phase III trials of prophylactic human papillomavirus (HPV)
virus-like particle (VLP) vaccines in young women are now largely completed. Two distinct …
virus-like particle (VLP) vaccines in young women are now largely completed. Two distinct …
[HTML][HTML] High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
LL Villa, RLR Costa, CA Petta, RP Andrade… - British Journal of …, 2006 - nature.com
Human papillomavirus (HPV) causes cervical, vulvar, and vaginal cancers, precancerous
dysplasia, and genital warts. We report data for the longest efficacy evaluation to date of a …
dysplasia, and genital warts. We report data for the longest efficacy evaluation to date of a …